Sunovion
Pharmaceutical company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Sunovion?
Summarize this article for a 10 year old
On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc.,[1] a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.
Company type | Subsidiary |
---|---|
Industry | Pharmaceuticals |
Founded | 1984 |
Headquarters | Marlborough, Massachusetts, United States |
Key people | Antony Loebel (President and CEO) |
Products | Latuda Aptiom Kynmobi Lonhala Magnair Lunesta |
Parent | Sumitomo Pharma |
Website | http://www.sunovion.com |
Sunovion was founded as Sepracor, Inc. in 1984 by Timothy J. Barberich, Steve Matson, and Bob Bratzler. Sepracor completed its initial public offering in 1991, trading on NASDAQ under the ticker SEPR. On October 12, 2010, Sepracor, Inc. was acquired by and became a standalone subsidiary of Sumitomo Pharma of Japan (then known as Sumitomo Dainippon Pharma). In April 2023, Sumitomo Pharma announced the combination of its U.S. subsidiaries, including Sunovion, to form Sumitomo Pharma America (SMPA).[2]